The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or without aura, Axsome Therapeutics announced. Meloxicam is a COX-2 preferential ...

Symbravo (meloxicam/rizatriptan) is a prescription drug approved to treat certain types of migraine. Symbravo comes as an oral tablet. Specifically, doctors prescribe Symbravo for adults to treat ...

The pharmacodynamic properties of meloxicam have been reviewed by various authors, including Noble & Balfour. [16] In this article, we focus on the main studies that have evaluated the affinity of ...

Credit: Axsome Therapeutics Symbravo is expected to be available in approximately 4 months. Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug ...

Laurie Knepper, MD, is an associate professor of neurology at the University of Pittsburgh School of Medicine The information here represents her research and knowledge as a medical professional.